This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-31 and is reviewed periodically as new material appears.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
=== Legal status === Bulevirtide was approved for medical use in the European Union in July 2020, in Canada in August 2025, and in the United States in May 2026. The US Food and Drug Administration granted the application for bulevirtide priority review, breakthrough therapy, and orphan drug designations.
== Reception and legacy == In August 1961, at the International Congress of Biochemistry in Moscow, Nirenberg presented the poly-U experiments – first to a small group, but then at Francis Crick's urging, again to about a thousand attendees. The work was very enthusiastically received, and Nirenberg became famous overnight. The paper describing the work was published the same month. The experiment ushered in a furious race to fully crack the genetic code. Nirenberg's main competition was the esteemed biochemist Severo Ochoa. Dr. Ochoa and Dr. Arthur Kornberg shared the 1959 Nobel Prize in Physiology or Medicine for their previous "discovery of the mechanisms in the biological synthesis of ribonucleic acid and deoxyribonucleic acid." However, many colleagues at the National Institutes of Health (NIH) supported Nirenberg, aware that it may lead to the first Nobel Prize by an intramural NIH scientist. DeWitt Stetten Jr., the NIH director who first hired Nirenberg, called this period of collaboration "NIH's finest hour." Indeed, "for their interpretation of the genetic code and its function in protein synthesis," Marshall W. Nirenberg, Robert W. Holley, and Har Gobind Khorana were awarded the 1968 Nobel Prize in Physiology or Medicine. Working independently, Dr. Holley (Cornell University) had discovered the exact chemical structure of transfer-RNA, and Dr. Khorana (University of Wisconsin in Madison) had mastered the synthesis of nucleic acids. Dr. Nirenberg showed - excluding nonsense codons - every combination of a triplet (i.e.
== Common applications == The focus of this section is on the recognised metalloids. Elements less often recognised as metalloids are ordinarily classified as either metals or nonmetals; some of these are included here for comparative purposes. Metalloids and their compounds are used in alloys, biological agents (toxicological, nutritional, and medicinal), catalysts, flame retardants, glasses (oxide and metallic), optical storage media and optoelectronics, pyrotechnics, semiconductors, and electronics.
Sources: en.wikipedia.org
=== Livestock feed === One of the major uses of soybeans globally is as livestock feed, predominantly in the form of soybean meal. In the European Union, for example, though it does not make up most of the weight of livestock feed, soybean meal provides around 60% of the protein fed to livestock. In the United States, 70 percent of soybean production is used for animal feed, with poultry being the number one livestock sector of soybean consumption. The American Soybean Association estimates that over 90% of U.S. soybeans are used as animal feed and 97% of soybean meal feeds livestock and poultry. Spring grasses are rich in omega-3 fatty acids, whereas soy is predominantly omega-6. The soybean hulls, which mainly consist of the outer coats of the beans removed before oil extraction, can also be fed to livestock and whole soybean seeds after processing.
== Musical style and influences == Rush's music has been described as progressive rock, hard rock, heavy metal and alternative rock. The band's musical style changed substantially over the years. Its debut album was strongly influenced by British blues-based hard rock and heavy metal: an amalgam of sounds and styles from such rock bands including the Beatles, Black Sabbath, the Who, Cream, and Led Zeppelin. Rush was increasingly influenced by bands of the British progressive rock movement of the mid-1970s, especially Pink Floyd, Genesis, Yes, and Jethro Tull. In the tradition of progressive rock, Rush wrote extended songs with irregular and shifting mood, timbre, and metre, combined with lyrics influenced by Ayn Rand. In the 1980s, Rush merged their sound with trends of this period experimenting with new wave, reggae, and pop rock. The era included the band's most extensive use of instruments such as synthesizers, sequencers, and electronic percussion. In the early 1990s, the band transformed their style once again, returning to a more grounded hard rock style, and simultaneously harmonize with the alternative rock movement. The songs released during this period have been described as "hooky and radio-friendly". The band experimented with fusing heavy metal and progressive rock in "new ways" during its latter years.
The first elections took place in January 1889 and the county council formally came into being on 1 April 1889. On that day its first official meeting was held at the old Shire Hall on Old Elvet in Durham, the courthouse (built 1811) which had served as the meeting place of the quarter sessions which preceded the county council. The first chairman of the council was John Lloyd Wharton, who was the Conservative Member of Parliament for Ripon (in Yorkshire); he had also been chairman of the Durham Quarter Sessions since 1871. Durham was the first county council to be controlled by the Labour Party, which won the most seats in 1919. In 1974, the county was redesignated as a non-metropolitan county under the Local Government Act 1972. As part of those reforms the county ceded territory in the north-east to the new county of Tyne and Wear and in the south-east to the new county of Cleveland, but gained the former Startforth Rural District covering the part of Teesdale south of the River Tees from the North Riding of Yorkshire, and Darlington was brought back under the county council's control. Until 1974, the lower tier of local government comprised numerous boroughs, urban districts and rural districts. The districts were also reorganised in 1974 into eight non-metropolitan districts: Chester-le-Street, Darlington, Derwentside, Durham, Easington, Sedgefield, Teesdale, and Wear Valley. In 1997, Darlington became a unitary authority, removing it from county council control.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.